Back to search results

Resistance Training for Older Adults with Mobility Concerns

This study is looking at how different biological factors related to aging affect how older adults respond to resistance training. You might be able to join if you are 65 or older, are mostly sedentary, and have some risk for mobility problems. Participants will take part in Progressive Resistance Training three times a week and Health Education once a week. Researchers will measure changes in your physical function and blood sugar levels after meals to see how well the training works. The study aims to enroll 300 people, but its current status is unclear.

Study design
This is an interventional study planning to enroll 300 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in Progressive Resistance Training three times a week and Health Education once a week. Your physical function and blood glucose will be measured at the beginning and after 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 6 months, as primary endpoints are measured at this time point.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06940037

The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults

Recruiting
NAAges 65+InterventionalBasic science
Mayo Clinic
~300 participants
Updated 2025-09-16 on ClinicalTrials.gov
What's tested:Progressive Resistance TrainingHealth Education

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Precisely define the variability in changes in physical function
Measured over baseline, 6 months
+1 more outcome measured

Conditions

Aging
Mobility Disability

Explore related trials

Ability to mobilizeAging

Where it's being run

2 sites across 2 states
Massachusetts1
Minnesota1

Study leadership

  • Nathan LeBrasseur, Ph.D, MS · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Amanda Tweed
[email protected]
507-255-6663
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

aged greater than or equal to 65 years
sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity
at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB
willing to be randomized into HE or PRT
willing to be transported or transport themselves to the clinical sites for the intervention and assessments

Exclusion

unwillingness to provide informed consent
participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months
an SPPB score of less than or equal to 3
osteoarthritis or condition with joint pain limiting daily life activities
significant weight loss or gain (7.5% of body weight) in past six months
current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)
clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the "normal limits', that are deemed to be of concern for participation in the study by the study physician
acute or terminal illness
Mini Mental State Exam (MMSE) \<23
myocardial infarction in the previous 6 months or other symptomatic coronary artery disease
New York Heart Association Class III or IV congestive heart failure
serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG
chronic obstructive pulmonary disease requiring oxygen therapy
upper or lower extremity fracture in the previous 6 months
uncontrolled hypertension (150/90 mm Hg)
neuromuscular diseases and/or drugs which affect neuromuscular function
current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy
allergy to lidocaine
presence of significant liver or renal disease (eGFR \< 45 mL/min)
diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus
HbA1c \> 7%
BMI \<21 or \>35 for men or \>40 for women
excessive alcohol intake (\>14 alcoholic beverages per wk.)
current tobacco use
current participation in any interventional clinical trial
current use of weight loss medications

What this trial measures

  • Precisely define the variability in changes in physical functionbaseline, 6 months

    Measured by the Short Physical Performance Battery (SPPB), a 0-12 categorical scale of walking speed, standing balance, and repeated sit-to-stand time, with higher scores reflecting better physical function.

  • Precisely define the variability in changes in blood glucose concentrations in response to a meal tolerance testbaseline, 6 months

    Blood glucose concentrations (millimoles/liter) will be measured in response to a physiologically relevant meal challenge. Lower values are indicative of better metabolic health.